Laurus Labs Ltd.
Research Laurus Labs Ltd. (LAURUSLABS.NS) on Bullrun: market cap INR 1.31T, P/E 98.0, dividend yield 0.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLAURUSLABS.NS
- ExchangeNSE
- CountryIndia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyINR
- Market capINR 1.31T
- P/E98.0
- Dividend yield0.1%
- Financial periodQ2 2026
- RevenueINR 20.26B
- Net incomeINR 3.68B
- Gross margin62.7%
Valuation Snapshot
latest market cap is INR 1.31T; P/E is 98.0; dividend yield is 0.1%.
Peer valuation comparison
Latest P/E is 97.96x versus a Healthcare sector median of 21.8x (349.4% above).
Latest dividend yield is 0.05% versus a Healthcare sector median of 2.4% (97.9% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | INR 1.31T | 98.0 | 0.1% | 2 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2 INR, yield 0.1%.
About Laurus Labs Ltd.
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology.
ETFs that hold Laurus Labs Ltd.
Laurus Labs Ltd. is one of the ten largest holdings of 2 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF | 0.42% | 0.55% |
| iShares MSCI EM Small Cap UCITS ETF USD (Dist) | 0.42% | 0.74% |
Compare every fund on the same index:
US-listed ETFs
Laurus Labs Ltd. is held by 42 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares Core MSCI Emerging Markets ETF (IEMG) | 0.04% | 0.09% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | 0.02% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | 0.06% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | 0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | 0.02% | 0.04% |
| iShares Core MSCI Total International Stock ETF (IXUS) | 0.02% | 0.07% |
| Avantis Emerging Markets Equity ETF (AVEM) | 0.02% | 0.33% |
| Schwab Emerging Markets Equity ETF (SCHE) | 0.05% | 0.06% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Laurus Labs Ltd.'s market cap?
Laurus Labs Ltd.'s market capitalization is INR 1.31T.
What is Laurus Labs Ltd.'s P/E ratio?
Laurus Labs Ltd.'s price-to-earnings (P/E) ratio is 98.0.
Does Laurus Labs Ltd. pay a dividend?
Laurus Labs Ltd. has a dividend yield of 0.1%.
What does Laurus Labs Ltd. do?
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development.